Chemical Component Summary | |
---|---|
Name | Amitriptyline |
Synonyms | 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine |
Identifiers | n/a |
Formula | C20 H23 N |
Molecular Weight | 277.403 |
Type | NON-POLYMER |
Isomeric SMILES | CN(C)CCC=C1c2ccccc2CCc3c1cccc3 |
InChI | InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3 |
InChIKey | KRMDCWKBEZIMAB-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 44 |
Chiral Atom Count | 0 |
Bond Count | 46 |
Aromatic Bond Count | 12 |
Drug Info: DrugBank
DrugBank ID | DB00321? |
---|---|
Name | Amitriptyline |
Groups | approved |
Description | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961.[A259342] Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.[A174661] |
Synonyms |
|
Brand Names |
|
Indication | This drug in indicated for the following conditions [FDA label]: Major depressive disorder in adults [L46357] Management of neuropathic pain in adults Prophylactic treatment of chronic tension-type headache (CTTH) in adults Prophylactic treatment of migraine in adults Treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products. This product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis [FDA label] Off-label uses: irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation, fibromyalgia, and insomnia |
Categories |
|
ATC-Code |
|
CAS number | 50-48-6 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Sodium-dependent noradrenaline transporter | MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRD... | unknown | inhibitor |
Sodium-dependent serotonin transporter | METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAV... | unknown | inhibitor |
5-hydroxytryptamine receptor 2A | MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSE... | unknown | antagonist |
5-hydroxytryptamine receptor 1A | MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCA... | unknown | inhibitor,inducer |
Delta-type opioid receptor | MEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAI... | unknown | agonist |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL629 |
PubChem | 2160 |
ChEMBL | CHEMBL629 |
ChEBI | CHEBI:2666 |
CCDC/CSD | YOVZEO |